REGKIRONA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, Romania

Active ingredients

The drug REGKIRONA contains one active pharmaceutical ingredient (API):

1 Regdanvimab UNII I0BGE6P6I6 - REGDANVIMAB

Regdanvimab is a recombinant human IgG1 monoclonal antibody that binds to the receptor binding domain (RBD) of the spike(s) protein of SARS-CoV-2 consequently blocking cellular entry and SARS-CoV-2 infection. Read about Regdanvimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REGKIRONA Concentrate for solution for infusion		MPI, EU: SmPC
REGKIRONA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BD06		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1865011
Country: FR	Base de données publique des médicaments	Identifier(s): 64499822
Country: IT	Agenzia del Farmaco	Identifier(s): 049765011
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093628
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100459976
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68266001